Shelley B. Thunen Sells 10,000 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $52.69, for a total transaction of $526,900.00. Following the transaction, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at $734,393.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

RxSight Price Performance

Shares of RXST stock opened at $61.68 on Friday. The company has a market cap of $2.29 billion, a P/E ratio of -43.13 and a beta of 1.21. The stock’s 50-day moving average is $52.59 and its 200 day moving average is $42.56. RxSight, Inc. has a 1-year low of $18.09 and a 1-year high of $61.85.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.10. The business had revenue of $28.58 million for the quarter, compared to analysts’ expectations of $28.60 million. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. On average, analysts anticipate that RxSight, Inc. will post -0.94 EPS for the current year.

Institutional Trading of RxSight

A number of institutional investors have recently bought and sold shares of the stock. Artisan Partners Limited Partnership raised its holdings in shares of RxSight by 17.3% in the third quarter. Artisan Partners Limited Partnership now owns 2,437,765 shares of the company’s stock worth $67,989,000 after buying an additional 359,295 shares during the last quarter. Vanguard Group Inc. raised its stake in RxSight by 21.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,433,953 shares of the company’s stock worth $39,993,000 after acquiring an additional 255,150 shares during the last quarter. Great Lakes Advisors LLC acquired a new stake in RxSight during the 4th quarter worth about $8,226,000. Lord Abbett & CO. LLC grew its stake in RxSight by 13.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 1,628,320 shares of the company’s stock valued at $45,414,000 after purchasing an additional 197,099 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of RxSight by 263.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 243,346 shares of the company’s stock valued at $6,787,000 after purchasing an additional 176,451 shares during the period. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Oppenheimer boosted their target price on RxSight from $54.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of RxSight in a research note on Thursday, April 11th. Stifel Nicolaus raised their price target on RxSight from $54.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Finally, JPMorgan Chase & Co. upped their price objective on shares of RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $49.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.